BRCA Gene Mutations Linked to aggressive Prostate Cancer, Annual Screening Urged
Table of Contents
A new study reveals men carrying BRCA1 and BRCA2 gene mutations face a substantially elevated risk of developing early and aggressive prostate cancer, prompting calls for annual screening starting at age 40. The research,presented at the European Society for Medical Oncology (ESMO) congress in Berlin,underscores the importance of proactive monitoring for individuals with these genetic predispositions.
The Genetic Link to Prostate Cancer
BRCA1 and BRCA2 are genes responsible for regulating DNA repair within cells. When mutations occur in these genes,the body’s ability to fix DNA damage is compromised,substantially increasing cancer risk. while widely known for their association with breast and ovarian cancer in women, these mutations also pose a serious threat to men, specifically increasing their susceptibility to prostate and pancreatic cancers.
The study, conducted across 65 centers in 20 countries with support from Cancer Research UK, found that men with a BRCA1 mutation were over three times more likely to develop aggressive prostate cancer compared to those without the mutation. Moreover, the risk of prostate cancer doubled for those carrying a BRCA2 mutation, and the average age of diagnosis decreased from 65 to 60.
angelina Jolie’s influence on Genetic Awareness
The spotlight on BRCA1 and BRCA2 mutations was significantly amplified by actress Angelina Jolie, who publicly revealed in 2013 that she carried a mutation in the BRCA1 gene. Jolie’s mother and aunt both succumbed to ovarian cancer, prompting her to undergo preventative mastectomy and ovary removal. Her brave decision, detailed in a New York Times article titled “My Medical Choice,” brought genetic testing and preventative healthcare to the forefront of public conversation.
The Case for Annual PSA testing
Experts emphasize that early detection is crucial for improving prostate cancer survival rates. Currently, the PSA test, which identifies prostate cancer markers in the blood, is considered an effective screening tool. “The risk of aggressive prostate cancer is significantly higher in men carrying BRCA1 and BRCA2 mutations,” stated Ros Eeles, Professor of Oncogenetics from the Institute of Cancer Research (ICR). “Until more sensitive tests are developed, annual PSA screening for these groups may enable detection of the disease at an early and treatable stage.”
Professor Eeles further urged regulatory authorities to update guidelines to offer annual PSA testing to men with BRCA1 or BRCA2 mutations, beginning at age 40. A five-year study involving over 3,000 men undergoing annual PSA tests demonstrated the potential of targeted screening in facilitating early diagnosis.
Data reveals a stark contrast in survival rates based on the stage of diagnosis: 90 percent of men diagnosed with early-stage prostate cancer are still alive 10 years later, a figure that plummets to below 20 percent when the disease is detected at a later stage. This underscores the life-saving potential of proactive screening for high-risk individuals.
The findings represent a critical step toward personalized cancer prevention, highlighting the need for increased awareness and access to genetic testing and screening
